Innoviva, Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| INVA | LLY | |
|---|---|---|
| Market Cap | $1.50 billion | $1.05 trillion |
| Revenue (TTM) | $440.00 million | $79.67 billion |
| Net Income (TTM) | $357.24 million | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| INVA | LLY | |
|---|---|---|
| P/E Ratio | 5.19 | 39.77 |
| Price / Book | 1.21 | 31.14 |
| Price / Sales | 3.41 | 13.24 |
INVA leads on 3 of 3 valuation factors.
Profitability
| INVA | LLY | |
|---|---|---|
| Net Margin | 81.19% | 33.53% |
| Return on Equity | 28.97% | 78.84% |
INVA and LLY split the profitability factors evenly.
Dividend
| INVA | LLY | |
|---|---|---|
| Dividend Yield | 4.69% | 0.58% |
| Payout Ratio | 24.33 | 23.23 |
INVA and LLY split the dividend factors evenly.
Risk & Sentiment
| INVA | LLY | |
|---|---|---|
| Short Interest | 19.43% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: INVA overview, INVA financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
